Novartis Danmark A.I CyberSecurity Scoring
15/12/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Novartis Danmark in 2026.
No incidents recorded for Novartis Danmark in 2026.
No incidents recorded for Novartis Danmark in 2026.
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
Latest updates, reports, and threat intel affecting the global network.
tls_opt_dtls_peer_connection_id_value_get() in subsys/net/lib/sockets/sockets_tls.c, which handles getsockopt(SOL_TLS, TLS_DTLS_PEER_CID_VALUE), passed the caller-supplied optval directly to mbedtls_ssl_get_peer_cid() without verifying the buffer was at least MBEDTLS_SSL_CID_OUT_LEN_MAX (default 32) bytes. mbedtls_ssl_get_peer_cid() copies the peer-negotiated DTLS Connection ID (length 1..MBEDTLS_SSL_CID_OUT_LEN_MAX) into that buffer without a destination-size parameter, so a caller-supplied optlen smaller than the CID causes a write of up to 31 bytes past the buffer end. In CONFIG_USERSPACE builds the getsockopt syscall verifier (z_vrfy_zsock_getsockopt) bounce-buffers the user's optval into a kernel allocation of exactly optlen bytes (k_usermode_alloc_from_copy -> z_thread_malloc), so an unprivileged user thread that passes a small optlen on a connected DTLS socket with Connection ID enabled induces a kernel-heap buffer overflow, with the overflowing content being the remote peer's CID. The defect requires CONFIG_MBEDTLS_SSL_DTLS_CONNECTION_ID, an established DTLS session with a negotiated peer CID, and (for the kernel-crossing case) CONFIG_USERSPACE. Introduced when the TLS_DTLS_CID option was added (v3.5.0). The fix rejects callers whose optlen is below MBEDTLS_SSL_CID_OUT_LEN_MAX with -EINVAL.
react18-use is a React 19 use hook shim. Between 2026-05-19 01:07:01 and 2026-05-19 15:20:43, the default branch contained malicious commits 7b79148d1495a2505f9277da295a98cf176f4496 through 7b79148d1495a2505f9277da295a98cf176f4496 that executed remote attacker-controlled code on developer machines during `npm install`. The commits were removed by force-push, but local clones, forks, and direct-SHA URLs may still contain them, and `npm install` against an affected checkout will still execute the code today. The package was not published to npm. `src/install.js` was added and wired into the `postinstall` script. It fetched a JavaScript payload from an attacker-controlled HTTPS endpoint (configurable via an environment variable), disabled TLS verification, and evaluated the response as code with `require` available. Execution was deliberately skipped on CI and cloud/serverless environments, targeting developer workstations. The second-stage payload was attacker-hosted and cannot be reconstructed. Assume full compromise of anything reachable from a Node process with the user's permissions. Those who ran `npm install` against an affected checkout on a developer machine on or after 2026-05-19 01:07:01 should treat the machine as compromised, rotate every credential the machine could reach, audit account activity since 2026-05-19 01:07:01, and clean local clones.
The UpdateHub management subsystem (subsys/mgmt/updatehub/updatehub.c) drives every update operation through a single file-scope ctx structure that holds the CoAP block context, payload buffer, status code, socket, and a one-element poll-fd array fds[1]. Access to ctx was not serialized, and prepare_fds() wrote ctx.fds[ctx.nfds] and incremented ctx.nfds with no bounds check. Two independent paths mutate ctx concurrently: the background autohandler running on the system workqueue, and user-triggered operations reached through the updatehub run shell command, direct API calls, or — since the operations are exposed as syscalls — userspace threads. When a second flow enters prepare_fds() while ctx.nfds is already 1, the write lands one element past the array; by struct layout it overlaps the adjacent ctx.sock/ctx.nfds members. More broadly, the unsynchronized sharing lets two flows interleave connection setup and teardown, double-closing a socket descriptor or scribbling the shared buffers. The result is corruption of the update subsystem's internal state and denial of service of the firmware-update path; the out-of-bounds write is contained within the ctx structure and there is no demonstrated path to memory outside it or to code execution. Triggering requires a local actor able to invoke update operations (or, with CONFIG_USERSPACE, an unprivileged userspace thread) and to win a timing race against the background handler; remote peers cannot control the race timing. The fix serializes the entry points with a mutex and adds a bounds check to prepare_fds().
The UpdateHub over-the-air update client's start_coap_client() in subsys/mgmt/updatehub/updatehub.c leaks the CoAP/DTLS socket descriptor on its connection-setup failure paths. The shared error: cleanup gated socket closing on a ret > 0 flag, but ret was set to -1 immediately after the socket was created, so when zsock_setsockopt() (DTLS) or zsock_connect() subsequently failed the gate was false and cleanup_connection() was never called. The open descriptor in the global ctx.sock was then overwritten by the next attempt, permanently leaking it from the socket / net_context pool until reboot. The failing setup path is reached every time the OTA client tries to contact the UpdateHub server and the connection cannot be established — driven automatically by the periodic autohandler() poll (and on demand via the updatehub_probe()/updatehub_update() API or the updatehub run shell command). The DTLS handshake/connect outcome is influenceable by a network or on-path attacker who drops, resets, or otherwise disrupts traffic to the server, and also fails naturally whenever the server is unreachable. Each failed attempt permanently leaks one descriptor; once the shared socket pool is exhausted, networking degrades device-wide until the device is rebooted, a denial-of-service condition. Severity is low because the leak rate is bounded by the configured OTA poll interval (default once per 24 hours), the effect is gradual and recovered by reboot, and only builds with the UpdateHub client enabled are affected. There is no memory-corruption, information-disclosure, or authentication impact.
Certain web interface components in affected TP-Link Aginet devices do not validate and sanitize user-supplied input properly before passing it to system-level command execution functions. An authenticated adjacent attacker may inject specially crafted input to execute arbitrary operation system commands with elevated privileges. Successful exploitation may allow execution of arbitrary system commands, potentially leading to full device compromise.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.